

Josã© Alexandre de Souza Crippa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2165013/publications.pdf>

Version: 2024-02-01

154
papers

8,074
citations

61857

43
h-index

58464

82
g-index

161
all docs

161
docs citations

161
times ranked

7695
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 15-20.	0.9	7
2	Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 658-669.	1.5	22
3	Harmine impairs memory performance of treated rats and nontreated cagemates.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 751-759.	1.3	2
4	Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. <i>Psychopharmacology</i> , 2022, 239, 1499-1507.	1.5	15
5	Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1076.	1.8	12
6	Circulating Endocannabinoids in Huntington's Disease: An Exploratory Cross-Sectional Study. <i>Journal of Huntington's Disease</i> , 2022, , 1-5.	0.9	0
7	The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 298-307.	0.9	11
8	Monitoring the Mental Health and Professional Overload of Health Workers in Brazil: A Longitudinal Study Considering the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2022, 13, 852157.	1.3	7
9	Is it the Ideal Time to Start Prescribing Cannabis Derivatives to Treat Endometriosis-associated Pain?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2022, 44, 449-451.	0.3	0
10	Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action. <i>Metabolic Brain Disease</i> , 2021, 36, 639-652.	1.4	27
11	Memory Bias and Personality Characteristics in College Students with Social Anxiety Disorder. <i>Trends in Psychiatry and Psychotherapy</i> , 2021, , .	0.4	1
12	A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 37-40.	1.1	3
13	Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 327-329.	0.7	12
14	Risk and Protective Factors for the Mental Health of Brazilian Healthcare Workers in the Frontline of COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 662742.	1.3	23
15	Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2120603.	2.8	47
16	Cannabidiol reverses memory impairments and activates components of the Akt/GSK3 β pathway in an experimental model of estrogen depletion. <i>Behavioural Brain Research</i> , 2021, 417, 113555.	1.2	3
17	Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification. <i>Schizophrenia Research</i> , 2021, 236, 104-114.	1.1	9
18	Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1264, 29-45.	0.8	47

#	ARTICLE	IF	CITATIONS
19	Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 467-476.	0.9	26
20	The first department of medical psychology in the world and its impact on medical education. <i>Revista Brasileira De Psiquiatria</i> , 2021, , .	0.9	0
21	Increased body sway in phobic patients exposed to images of spiders. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 477-483.	0.9	0
22	Oral Cannabidiol Does Not Convert to Δ^8 -THC or Δ^9 -THC in Humans: A Pharmacokinetic Study in Healthy Subjects. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 89-98.	1.5	30
23	Biological bases for a possible effect of cannabidiol in Parkinson's disease. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 218-224.	0.9	18
24	In-tube solid-phase microextraction with a dummy molecularly imprinted monolithic capillary coupled to ultra-performance liquid chromatography-tandem mass spectrometry to determine cannabinoids in plasma samples. <i>Analytica Chimica Acta</i> , 2020, 1099, 145-154.	2.6	34
25	Cannabidiol-induced panicolytic-like effects and fear-induced antinociception impairment: the role of the CB1 receptor in the ventromedial hypothalamus. <i>Psychopharmacology</i> , 2020, 237, 1063-1079.	1.5	8
26	Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2020, 34, 189-196.	2.0	69
27	The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 236-246.	2.9	9
28	Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias. <i>Journal of Neural Transmission</i> , 2020, 127, 1359-1367.	1.4	13
29	Prof. Elisaldo Araújo Carlini, Cannabis and Cannabinoids Research Pioneer (June 9, 1930–September 16,) Tj ETQq1,1 0.784314 rgB	1.5	0
30	Proneness, urbanicity, trauma, and cannabis triggering psychotic states in large urban centers. <i>Current Opinion in Psychiatry</i> , 2020, 33, 250-254.	3.1	1
31	Ensuring access to safe, effective, and affordable cannabis-based medicines. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 630-634.	1.1	14
32	Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 517-526.	1.5	46
33	Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. <i>Neuroscience Letters</i> , 2020, 729, 135020.	1.0	16
34	Intraperitoneal cannabidiol attenuates neonatal germinal matrix hemorrhage-induced neuroinflammation and perilesional apoptosis. <i>Neurological Research</i> , 2019, 41, 980-990.	0.6	9
35	Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. <i>CNS Drugs</i> , 2019, 33, 1031-1038.	2.7	14
36	Clinical validity and intrarater and test-retest reliability of the Structured Clinical Interview for DSM-5 – Clinician Version (SCID-5/CV). <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 754-760.	1.0	145

#	ARTICLE	IF	CITATIONS
37	Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 121-133.	1.8	41
38	Personality Inventory for DSM-5 (PID-5): cross-cultural adaptation and content validity in the Brazilian context. <i>Trends in Psychiatry and Psychotherapy</i> , 2019, 41, 297-300.	0.4	11
39	Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. <i>Neuropharmacology</i> , 2019, 155, 44-53.	2.0	15
40	Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531984577.	1.2	25
41	O uso do canabidiol (CBD) no tratamento da doença de Parkinson e suas comorbidades. , 2019, 98, 46-51.	0.0	3
42	Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. <i>Brain Research</i> , 2019, 1715, 156-164.	1.1	67
43	The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 101, 78-84.	2.9	51
44	DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF- κ B activity dependent on A2A receptor. <i>Toxicology and Applied Pharmacology</i> , 2019, 368, 63-71.	1.3	33
45	Association Between Physician Depressive Symptoms and Medical Errors. <i>JAMA Network Open</i> , 2019, 2, e1916097.	2.8	88
46	Epigenetic variation at the SLC6A4 gene promoter in mother-child pairs with major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 245, 716-723.	2.0	17
47	Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. <i>Brain Research Bulletin</i> , 2018, 139, 1-8.	1.4	38
48	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 1-10.	1.5	17
49	Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 644-646.	0.7	8
50	Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. <i>Translational Psychiatry</i> , 2018, 8, 176.	2.4	50
51	Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire. <i>PLoS ONE</i> , 2018, 13, e0203531.	1.1	3
52	Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. <i>Frontiers in Immunology</i> , 2018, 9, 2009.	2.2	187
53	17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD). <i>Schizophrenia Bulletin</i> , 2018, 44, S28-S28.	2.3	1
54	Clinical issues in cannabis use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2495-2498.	1.1	20

#	ARTICLE	IF	CITATIONS
55	No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 315.	1.6	70
56	Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. <i>Frontiers in Pharmacology</i> , 2018, 9, 482.	1.6	110
57	Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology. <i>Revista De Psiquiatria Clinica</i> , 2018, 45, 7-11.	0.6	5
58	Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System. <i>CNS Drugs</i> , 2018, 32, 697-712.	2.7	37
59	Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia. <i>Frontiers in Pharmacology</i> , 2018, 9, 901.	1.6	36
60	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. <i>Analytica Chimica Acta</i> , 2018, 1044, 12-28.	2.6	43
61	Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. <i>Chemico-Biological Interactions</i> , 2018, 291, 81-86.	1.7	29
62	Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. <i>Neuroscience Letters</i> , 2018, 682, 62-68.	1.0	23
63	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	1.5	27
64	Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report. <i>Journal of Psychedelic Studies</i> , 2017, 1, 35-39.	0.5	5
65	Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 698-711.	1.0	111
66	A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3587-3596.	1.9	33
67	Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits. <i>Neuroscience</i> , 2017, 350, 85-93.	1.1	32
68	A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 81-86.	1.5	47
69	Psychometric properties of the dimensional anxiety scales for DSM-5 in a Brazilian community sample. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	1.1	10
70	Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. <i>Frontiers in Pharmacology</i> , 2017, 8, 131.	1.6	56
71	Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats. <i>Frontiers in Pharmacology</i> , 2017, 8, 391.	1.6	36
72	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): transcultural adaptation of the Brazilian version. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 10-19.	0.6	28

#	ARTICLE	IF	CITATIONS
73	Early interventions for the prevention of PTSD in adults: a systematic literature review. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 23-29.	0.6	10
74	Can anxiety increase tremors in patients with Parkinson's disease? An experimental model. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 85-88.	0.6	5
75	False memories in social anxiety disorder. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 113-116.	0.6	0
76	Determination of Drugs in Plasma Samples by High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Schizophrenic Patients. <i>Journal of Analytical Toxicology</i> , 2016, 40, bk107.	1.7	34
77	Mental health in medical residents: relationship with personal, work-related, and sociodemographic variables. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 318-324.	0.9	13
78	Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. <i>PLoS ONE</i> , 2016, 11, e0158779.	1.1	35
79	Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 65-72.	0.9	98
80	Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. <i>Frontiers in Pharmacology</i> , 2016, 7, 303.	1.6	24
81	Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. <i>Frontiers in Pharmacology</i> , 2016, 7, 343.	1.6	46
82	Δ ⁹ -THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol. <i>Frontiers in Pharmacology</i> , 2016, 7, 359.	1.6	60
83	Heritability of social anxiety disorder: a systematic review of methodological designs. <i>Revista De Psiquiatria Clinica</i> , 2016, 43, 83-92.	0.6	10
84	Factor Structure, Reliability, and Item Parameters of the Brazilian-Portuguese Version of the GAD-7 Questionnaire. <i>Temas Em Psicologia</i> , 2016, 24, 367-376.	0.3	101
85	Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 195-205.	1.0	65
86	Facial emotion recognition in social anxiety: The influence of dynamic information. <i>Psychology and Neuroscience</i> , 2016, 9, 1-11.	0.5	24
87	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. <i>NeuroImage: Clinical</i> , 2016, 12, 1-15.	1.4	107
88	Classical hallucinogens and neuroimaging: A systematic review of human studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 715-728.	2.9	79
89	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 77-81.	0.7	364
90	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 193-213.	1.2	204

#	ARTICLE	IF	CITATIONS
91	Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 220-221.	1.1	22
92	Letter to the Editor. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2016, 38, 116-117.	0.5	1
93	Facial emotion processing in patients with social anxiety disorder and Williams' Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 182-191.	1.4	20
94	The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network. <i>PLoS ONE</i> , 2015, 10, e0118143.	1.1	308
95	Editorial (Thematic Issue: Translational Neuroscience: Narrowing Distances for Future Discoveries). <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 962-962.	0.8	1
96	Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. <i>European Neuropsychopharmacology</i> , 2015, 25, 483-492.	0.3	145
97	Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon. <i>European Journal of Pharmacology</i> , 2015, 758, 153-163.	1.7	24
98	Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (<i>Danio rerio</i>). <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 210-216.	1.3	32
99	Phytocannabinoids and epilepsy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 135-143.	0.7	60
100	Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. <i>Molecular Neurobiology</i> , 2015, 52, 26-37.	1.9	30
101	Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 970-978.	0.8	10
102	Evaluation of the Psychometric Properties of the Cognitive Distortions Questionnaire (CD-Quest) in a Sample of Undergraduate Students. <i>Innovations in Clinical Neuroscience</i> , 2015, 12, 20-7.	0.1	27
103	Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. <i>Frontiers in Pharmacology</i> , 2014, 5, 10.	1.6	59
104	Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 30-36.	1.2	21
105	Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 1088-1098.	2.0	244
106	Cannabidiol and endogenous opioid peptide-mediated mechanisms modulate antinociception induced by transcutaneous electrostimulation of the peripheral nervous system. <i>Journal of the Neurological Sciences</i> , 2014, 347, 82-89.	0.3	13
107	Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection. <i>Molecular Neurobiology</i> , 2014, 49, 222-233.	1.9	69
108	Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 953-960.	0.8	116

#	ARTICLE	IF	CITATIONS
109	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	0.6	26
110	Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. <i>Journal of Psychopharmacology</i> , 2013, 27, 312-316.	2.0	64
111	Disability Profile/Clinician-Rated: Validity for Brazilian University Students with Social Anxiety Disorder. <i>Spanish Journal of Psychology</i> , 2013, 16, E48.	1.1	1
112	Cannabidiol for the treatment of <i>cannabis</i> withdrawal syndrome: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 162-164.	0.7	82
113	Assessment of referrals to an OT consultation-liaison service: a retrospective and comparative study. <i>Scandinavian Journal of Occupational Therapy</i> , 2012, 19, 84-91.	1.1	1
114	A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation. <i>Current Pharmaceutical Design</i> , 2012, 18, 5131-5140.	0.9	174
115	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	0.9	64
116	Utiliza�o do Invent�rio de Habilidades sociais no diagn�stico do Transtorno de Ansiedade Social. <i>Psicologia: Reflexao E Critica</i> , 2012, 25, 467-476.	0.4	10
117	Transtorno de ansiedade social e habilidades sociais de falar em p�blico: estudo experimental. <i>Estudos E Pesquisas Em Psicologia</i> , 2012, 12, .	0.0	2
118	Aspectos cognitivos do falar em p�blico: valida�o de uma escala de autoavalia�o para universit�rios brasileiros. <i>Revista De Psiquiatria Clinica</i> , 2012, 39, 48-53.	0.6	13
119	Social phobia in Brazilian university students: Prevalence, under-recognition and academic impairment in women. <i>Journal of Affective Disorders</i> , 2012, 136, 857-861.	2.0	57
120	Interaction between cannabidiol (CBD) and �9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. <i>Psychopharmacology</i> , 2012, 219, 247-249.	1.5	78
121	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	0.9	47
122	Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Na�ve Social Phobia Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1219-1226.	2.8	585
123	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>Journal of Psychopharmacology</i> , 2011, 25, 121-130.	2.0	406
124	Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2011, 125, 1-12.	1.1	69
125	Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 255-262.	1.2	35
126	Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 877-886.	2.5	40

#	ARTICLE	IF	CITATIONS
127	Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. <i>Current Drug Safety</i> , 2011, 6, 237-249.	0.3	422
128	Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. <i>Brain Research</i> , 2011, 1388, 167-177.	1.1	142
129	Social anxiety disorder women easily recognize fearful, sad and happy faces: The influence of gender. <i>Journal of Psychiatric Research</i> , 2010, 44, 535-540.	1.5	62
130	Further Study of the Psychometric Qualities of a Brief Screening Tool for Social Phobia (MINI-SPIN) Applied to Clinical and Nonclinical Samples. <i>Perspectives in Psychiatric Care</i> , 2010, 46, 266-278.	0.9	19
131	Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 56-61.	0.9	121
132	The Fast Alcohol Screening Test (FAST) is as Good as the AUDIT to Screen Alcohol Use Disorders. <i>Substance Use and Misuse</i> , 2010, 45, 1542-1557.	0.7	21
133	Evaluation of the psychometric properties of the Social Phobia Inventory in university students. <i>Comprehensive Psychiatry</i> , 2010, 51, 630-640.	1.5	32
134	Neuroimaging in social anxiety disorder: A systematic review of the literature. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 565-580.	2.5	242
135	Agomelatine in the treatment of social anxiety disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1357-1358.	2.5	14
136	Instituto Nacional de Ciência e Tecnologia em Medicina Translacional (INCT-TM): abordagens metodológicas. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 83-90.	0.9	13
137	Cannabis sativa: a planta que pode produzir efeitos indesejáveis e também tratá-los. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 51-52.	0.9	15
138	Cross-cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 25-29.	0.9	39
139	Arthur Bispo do Rosário (1909?-1989): Insanity and Art. <i>American Journal of Psychiatry</i> , 2009, 166, 1117-1117.	4.0	0
140	Does social phobia remain the 'Ugly Duckling' of anxiety disorders?. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 297-299.	0.9	13
141	Magnetic resonance spectroscopy in anxiety disorders. <i>Acta Neuropsychiatrica</i> , 2008, 20, 56-71.	1.0	20
142	Comparability Between Telephone and Face-to-Face Structured Clinical Interview for DSM-IV in Assessing Social Anxiety Disorder. <i>Perspectives in Psychiatric Care</i> , 2008, 44, 241-247.	0.9	96
143	Structural magnetic resonance imaging in anxiety disorders: an update of research findings. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 251-264.	0.9	63
144	Escala para auto-avaliação ao falar em público (SSPS): adaptação transcultural e consistência interna da versão brasileira. <i>Revista De Psiquiatria Clinica</i> , 2008, 35, 207-211.	0.6	23

#	ARTICLE	IF	CITATIONS
145	Are there differences between early- and late-onset social anxiety disorder?. Revista Brasileira De Psiquiatria, 2007, 29, 195-196.	0.9	15
146	Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. European Psychiatry, 2006, 21, 291-299.	0.1	47
147	Cross-cultural validation of the Brief Social Phobia Scale for use in Portuguese and the development of a structured interview guide. Revista Brasileira De Psiquiatria, 2006, 28, 212-217.	0.9	11
148	Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology, 2004, 29, 417-426.	2.8	239
149	Electrodermally Nonresponsive Schizophrenia Patients Make More Errors in the Stroop Color Word Test, Indicating Selective Attention Deficit. Schizophrenia Bulletin, 2002, 28, 459-466.	2.3	11
150	Lipoma adhered to the corpus callosum in a schizophrenic patient with severe positive symptoms that responded to clozapine. Acta Neuropsychiatrica, 2002, 14, 36-38.	1.0	5
151	Structural imaging of other anxiety disorders. , 0, , 274-287.		0
152	Social Anxiety Disorder, Fear of Public Speaking, and the use of Assessment Instruments. , 0, , .		2
153	Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations. Frontiers in Pharmacology, 0, 13, .	1.6	8
154	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A <i>Post Hoc</i> Exploratory Analysis of Phase 2/3 Clinical Trial. Cannabis and Cannabinoid Research, 0, , .	1.5	4